Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | TERT | O14746 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | PPARD | Q03181 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | TOP1 | P11387 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910291 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL8813801 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL1740121 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL3413043 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL1739857 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL1738577 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL7300136 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL38571 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL8813806 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL910387 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170192023-A1 | METHODS, COMPOSITIONS, AND KITS FOR ANALYSIS OF STRUCTURALLY DIVERSE COMPLEX LIPIDS | METABOLON, INC. | 2017-07-06 | — | — | US | claimed |
| EP-3174991-A1 | METHODS, COMPOSITIONS, AND KITS FOR ANALYSIS OF STRUCTURALLY DIVERSE COMPLEX LIPIDS | Metabolon, Inc. (US) | 2017-06-07 | — | — | EP | claimed |
| WO-2016019140-A1 | METHODS, COMPOSITIONS, AND KITS FOR ANALYSIS OF STRUCTURALLY DIVERSE COMPLEX LIPIDS | METABOLON, INC. (US) | 2016-02-04 | — | — | WO | claimed |
| US-20100290983-A1 | Compositions and Methods for Drug Delivery | BAXTER INTERNATIONAL INC. (US) | 2010-11-18 | — | — | US | claimed |
| US-20090285888-A1 | DERIVATIVES OF DIHYDROXYPHENYLALANINE | ELLNEUROXX LTD. (DE) | 2009-11-19 | — | — | US | claimed |
| US-20080234337-A1 | Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-25 | — | — | US | claimed |
| US-20080021021-A1 | Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | claimed |
| EP-1879880-A2 | DIHYDROXYPHENYLALANINE DERIVATIVES | Ellneuroxx Ltd. (DE) | 2008-01-23 | — | — | EP | claimed |
| EP-1782829-A1 | PREVENTIVE AND/OR REMEDY FOR HYPERKALEMIA CONTAINING EP4 AGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-09 | — | — | EP | claimed |
| WO-2006119758-A2 | DIHYDROXYPHENYLALANINE DERIVATIVES | ELLNEUROXX LTD. (DE) | 2006-11-16 | — | — | WO | claimed |
| EP-3174991-B1 | METHODS, COMPOSITIONS, AND KITS FOR ANALYSIS OF STRUCTURALLY DIVERSE COMPLEX LIPIDS | METABOLON INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11181535-B2 | Isotopically-labeled cholesteryl ester internal standard composition and kit | METABOLON, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210251900-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | BAXTER HEALTHCARE SA (CH) | 2021-08-19 | — | — | US | disclosed |
| US-10952965-B2 | Compositions and methods for drug delivery | BAXTER INTERNATIONAL INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | NANOSCIENCE FOR LIFE GMBH & COKG (DE) | 2019-03-26 | — | — | US | disclosed |
| US-5478809-A | Blood disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0641776-A2 | Thioglycerol derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0638588-A1 | Derivatives of 6,7-Dihydroxy-4-thiaheptonic acid and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| EP-0604945-A1 | TAN-1511, its derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0604957-A1 | 2-Amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285888-A1 | DERIVATIVES OF DIHYDROXYPHENYLALANINE | HTT, NLN, SNCA | FAAH 4423/4885TRPV1 4807/4885TERT 3906/4885 |
| US-20210251900-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | SGMS1, CETP, APOB | FAAH 1793/4885TRPV1 4688/4885TERT 3384/4885 |
| US-20100290983-A1 | Compositions and Methods for Drug Delivery | SGMS1, CETP, APOB | FAAH 1793/4885TRPV1 4688/4885TERT 3384/4885 |
| US-20080234337-A1 | Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist | KCNJ4, KCNK4, KCNA4 | FAAH 639/4885TRPV1 63/4885TERT 4777/4885 |
| US-20080021021-A1 | Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist | PTGER4, PTGES3, CYSLTR1 | FAAH 667/4885TRPV1 102/4885TERT 4589/4885 |
| US-10952965-B2 | Compositions and methods for drug delivery | SGMS1, CETP, APOB | FAAH 1793/4885TRPV1 4688/4885TERT 3384/4885 |
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | AGL, LIPA, MGLL | FAAH 394/4885TRPV1 3946/4885TERT 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.